EBITDA Margin % is calculated as EBITDA divided by its Revenue. Apontis Pharma AG's EBITDA for the
six
months ended in Jun. 2025 was €1.53 Mil. Apontis Pharma AG's Revenue for the
six
months ended in Jun. 2025 was €26.03 Mil. Therefore, Apontis Pharma AG's EBITDA margin for the quarter that ended in Jun. 2025 was 5.87%.
Apontis Pharma AG (FRA:APPH) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Apontis Pharma AG EBITDA Margin % Related Terms
Apontis Pharma AG EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Apontis Pharma AG's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:APPH vs ZTS, UTHR, NBIX: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Apontis Pharma AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apontis Pharma AG EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Apontis Pharma AG's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Apontis Pharma AG's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apontis Pharma AG (FRA:APPH) has a EBITDA Margin % of 5.87% as of Jun. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Apontis Pharma AG and its competitors. This is 60% above median its historical median of 3.68.
Is Apontis Pharma AG's EBITDA Margin % too high?
Apontis Pharma AG's current EBITDA Margin % of 5.87% is 60% above median its 10-year median of 3.68. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Apontis Pharma AG's value of 5.87% is 52.8% below this industry median. Overall, Apontis Pharma AG has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Apontis Pharma AG's EBITDA Margin % compare to ZTS and UTHR?
Apontis Pharma AG's EBITDA Margin % of 5.87% can be compared against companies in the Drug Manufacturers industry. The industry median EBITDA Margin % is 12.44. Apontis Pharma AG's value of 5.87% is 52.8% below this benchmark. While the company's 10-year median is 3.68 vs. the industry median of 12.44, Apontis Pharma AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apontis Pharma AG's current EBITDA Margin % of 5.87% is 52.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Apontis Pharma AG and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apontis Pharma AG's current EBITDA Margin % is 5.87%, which is 60% above median its own 10-year median of 3.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apontis Pharma AG stock overvalued right now?
Apontis Pharma AG (FRA:APPH) has a current EBITDA Margin % of 5.87%. The stock's GF Value™ is €10.46, compared to a current price of €11.00 — trading 5.2% above its estimated fair value. The current EBITDA Margin % is 5.87%, which is 60% above median its 10-year median of 3.68 and 52.8% below the Drug Manufacturers industry median of 12.44. Apontis Pharma AG's overall GF Score™ is 17/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Apontis Pharma AG (FRA:APPH), the current EBITDA Margin % is 5.87% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apontis Pharma AG (FRA:APPH) Overvalued in 2026?
Based on GuruFocus' analysis, Apontis Pharma AG stock appears to be overvalued.
The current stock price of €11.00 is trading 5.2% above its estimated GF Value™ of €10.46.
Key valuation signals for FRA:APPH:
EBITDA Margin %: 5.87% (60% above median its 10-year median of 3.68)
GF Value™: €10.46 vs. price of €11.00 (5.2% above fair value)
Industry Position: 52.8% below the Drug Manufacturers median
No single metric tells the full story. See the FRA:APPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apontis Pharma AG is a pharmaceutical company specializing in single pills in Germany. single pills combine two to three generic active ingredients in a single dosage form. The company develops, promotes, and sells a broad portfolio of single pills and other pharmaceutical products, with a special focus on cardiovascular diseases. The company markets drugs in the disease areas of respiratory diseases and diabetes as part of co-marketing/co-promotion.
17GF Score
Get the complete analysis for FRA:APPH
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:APPH has been successfully added to your 
